-
09
2023
Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment
Caliway announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage 2 study.
-
09
2023
The Positive Topline Results from the CBL-514 Phase 2 Study for Dercum’s Disease Showed 64.5% of Painful Lipomas with Complete Clearance or Dimensions Reduction of more than 50% and Significantly Reduced Pain by 4.7 Points
CBL-0201DD Phase 2 study met the primary and all secondary endpoints.
-
07
2023
Caliway Receives IND approval from the U.S. FDA for the CBL-0205 Phase 2b Study Evaluating CBL-514 in Abdominal Subcutaneous Fat Reduction
Caliway announces that the U.S. FDA has approved the company’s IND application for CBL-514 injection’s CBL-0205 Phase 2b Study.
-
-
06
2023
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
The highest dose of CBL-514 treatment demonstrated the best efficacy, 87.5% of thighs achieved at least 1-level improvement in cellulite severity two weeks after CBL-514 treatment.
-
05
2023
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
The study is expected to complete in Q2 2024, and the topline results are anticipated in Q3 2024.
-
05
2023
Caliway Has Been Featured In Clinical Trial Arena Pipeline Moves
Clinical Trial Arena: May 2nd Pipeline Moves - Completion of Phase IIa non-malignant disorder trial
-
04
2023
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in a Phase 2-Stage 2 Study Evaluating the Efficacy of CBL-514 in Treating Moderate to Severe Cellulite
The subject recruitment and treatment in CBL-0201EFP Phase 2-Stage 1 is completed.
